DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Bavituximab is an investigational drug.
There have been 26 clinical trials for Bavituximab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2013.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, and Carcinoma. The leading clinical trial sponsors are Peregrine Pharmaceuticals, University of Texas Southwestern Medical Center, and National Comprehensive Cancer Network.
There are thirty-seven US patents protecting this investigational drug and eight hundred and sixty-six international patents.
Recent Clinical Trials for Bavituximab
|1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck||University of Maryland, Baltimore||Phase 2|
|An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients||Merck Sharp & Dohme Corp.||Phase 2|
|An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients||Oncologie Inc.||Phase 2|
Top disease conditions for Bavituximab
Top clinical trial sponsors for Bavituximab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Bavituximab||⤷ Try it Free||Multispecific constructs||AbbVie Stemcentrx LLC (North Chicago, IL)||⤷ Try it Free|
|Bavituximab||⤷ Try it Free||.beta.-glucan methods and compositions that affect the tumor microenvironment||BIOTHERA, INC. (Eagan, MN)||⤷ Try it Free|
|Bavituximab||⤷ Try it Free||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||⤷ Try it Free|
|Bavituximab||⤷ Try it Free||Method of treating pancreatic cancer||ChemoCentryx, Inc. (Mountain View, CA)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Bavituximab||Canada||CA2900764||2033-02-08||⤷ Try it Free|
|Bavituximab||European Patent Office||EP2954056||2033-02-08||⤷ Try it Free|
|Bavituximab||Hong Kong||HK1218930||2033-02-08||⤷ Try it Free|
|Bavituximab||Japan||JP2016509014||2033-02-08||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|